| Year |
Citation |
Score |
| 2022 |
Obst-Sander U, Ricci A, Kuhn B, Friess T, Koldewey P, Kuglstatter A, Hewings D, Goergler A, Steiner S, Rueher D, Imhoff MP, Raschetti N, Marty HP, Dietzig A, Rynn C, ... ... Pao W, et al. Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib. Journal of Medicinal Chemistry. PMID 36178776 DOI: 10.1021/acs.jmedchem.2c00893 |
0.497 |
|
| 2019 |
Riely GJ, Lovly CM, Messina CG, Bienert S, Alexander K, Pao W, Baxi S, Doebele RC. Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC. Journal of Clinical Oncology. 37: 9062-9062. DOI: 10.1200/Jco.2019.37.15_Suppl.9062 |
0.386 |
|
| 2019 |
Riely G, Lovly C, Messina C, Bienert S, Alexander K, Pao W, Magee K, Baxi S, Doebele R. P1.01-25 Real-World Outcomes of Advanced NSCLC Patients with Common and Uncommon/Complex EGFR Mutation Profiles Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.740 |
0.454 |
|
| 2017 |
Horn L, Gettinger S, Camidge DR, Smit EF, Janjigian YY, Miller VA, Pao W, Freiwald M, Fan J, Wang B, Chand VK, Groen HJM. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Lung Cancer (Amsterdam, Netherlands). 113: 51-58. PMID 29110849 DOI: 10.1016/J.Lungcan.2017.08.014 |
0.58 |
|
| 2017 |
Arbour KC, Kris MG, Riely GJ, Ni A, Beal K, Daras M, Hayes SA, Young RJ, Rodriguez CR, Ahn L, Pao W, Yu HA. Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases. Cancer. PMID 28940498 DOI: 10.1002/Cncr.30990 |
0.444 |
|
| 2017 |
Ichihara E, Westover D, Meador CB, Yan Y, Bauer JA, Lu P, Ye F, Kulick A, De Stanchina E, McEwen R, Ladanyi M, Cross D, Pao W, Lovly CM. SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer. Cancer Research. PMID 28416483 DOI: 10.1158/0008-5472.Can-16-2300 |
0.582 |
|
| 2017 |
Hartmaier RJ, Charo J, Fabrizio D, Goldberg ME, Albacker LA, Pao W, Chmielecki J. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies. Genome Medicine. 9: 16. PMID 28231819 DOI: 10.1186/S13073-017-0408-2 |
0.56 |
|
| 2017 |
Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN, Zent R, Clark PE. Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms Tumors. Molecular Oncology. PMID 28188683 DOI: 10.1002/1878-0261.12044 |
0.386 |
|
| 2017 |
Smit E, Soria J, Janjigian Y, Groen H, Pao W, Calvo E, Gazzah A, Fan J, Ould-Kaci M, Horn L. Afatinib (A) plus cetuximab (C) in the treatment of patients (pts) with NSCLC: The story so far Annals of Oncology. 28: ii30-ii31. DOI: 10.1093/Annonc/Mdx091.006 |
0.312 |
|
| 2016 |
Yu HA, Sima C, Feldman D, Liu LL, Vaitheesvaran B, Cross J, Rudin CM, Kris MG, Pao W, Michor F, Riely GJ. Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28073786 DOI: 10.1093/Annonc/Mdw556 |
0.508 |
|
| 2016 |
Davidson NE, Armstrong SA, Coussens LM, Cruz-Correa MR, DeBerardinis RJ, Doroshow JH, Foti M, Hwu P, Kensler TW, Morrow M, Mulligan CG, Pao W, Platz EA, Smith TJ, Willman CL. AACR Cancer Progress Report 2016. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 22: S1-S137. PMID 27697776 DOI: 10.1158/1078-0432.Ccr-16-1993 |
0.301 |
|
| 2016 |
Ortiz-Cuaran S, Scheffler M, Plenker D, Dahmen I, Scheel A, Fernandez-Cuesta L, Meder L, Lovly CM, Persigehl T, Merkelbach-Bruse S, Bos M, Michels S, Fischer R, Albus K, König K, ... ... Pao W, et al. Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27252416 DOI: 10.1158/1078-0432.Ccr-15-1915 |
0.511 |
|
| 2016 |
Gao SP, Chang Q, Mao N, Daly LA, Vogel R, Chan T, Liu SH, Bournazou E, Schori E, Zhang H, Red Brewer M, Pao W, Morris L, Ladanyi M, Arcila M, et al. JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. Science Signaling. 9: ra33. PMID 27025877 DOI: 10.1126/Scisignal.Aac8460 |
0.574 |
|
| 2016 |
Heist RS, Shim HS, Gingipally S, Mino-Kenudson M, Le L, Gainor JF, Zheng Z, Aryee M, Xia J, Jia P, Jin H, Zhao Z, Pao W, Engelman JA, Iafrate AJ. MET Exon 14 Skipping in Non-Small Cell Lung Cancer. The Oncologist. PMID 27022036 DOI: 10.1634/Theoncologist.2015-0510 |
0.484 |
|
| 2016 |
Warner JL, Wang L, Pao W, Sosman JA, Atreya RV, Carney P, Levy MA. CUSTOM-SEQ: A Prototype for Oncology Rapid Learning in a Comprehensive EHR Environment. Journal of the American Medical Informatics Association : Jamia. PMID 27008846 DOI: 10.1093/Jamia/Ocw008 |
0.41 |
|
| 2016 |
Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovly CM, Meador CB, Ye F, Lu P, Balko JM, Colvin DC, Cates JM, Pao W, Gray NS, Chen J. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Research. PMID 26744526 DOI: 10.1158/0008-5472.Can-15-0717 |
0.58 |
|
| 2016 |
Wang Z, Seow WJ, Shiraishi K, Hsiung CA, Matsuo K, Liu J, Chen K, Yamji T, Yang Y, Chang IS, Wu C, Hong YC, Burdett L, Wyatt K, Chung CC, ... ... Pao W, et al. Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. Human Molecular Genetics. PMID 26732429 DOI: 10.1093/Hmg/Ddv494 |
0.349 |
|
| 2015 |
Liu LL, Li F, Pao W, Michor F. Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients. Plos One. 10: e0141665. PMID 26536620 DOI: 10.1371/Journal.Pone.0141665 |
0.493 |
|
| 2015 |
Pirazzoli V, Ayeni D, Meador CB, Sanganahalli B, Hyder F, de Stanchina E, Goldberg SB, Pao W, Politi K. Afatinib plus cetuximab delays resistance compared to single agent erlotinib or afatinib in mouse models of TKI-naïve EGFR L858R-induced lung adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26341921 DOI: 10.1158/1078-0432.Ccr-15-0620 |
0.555 |
|
| 2015 |
Mumenthaler SM, Foo J, Choi NC, Heise N, Leder K, Agus DB, Pao W, Michor F, Mallick P. The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Informatics. 14: 19-31. PMID 26244007 DOI: 10.4137/Cin.S19338 |
0.442 |
|
| 2015 |
Zeng C, Wen W, Morgans AK, Pao W, Shu XO, Zheng W. Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010. Jama Oncology. 1: 88-96. PMID 26182310 DOI: 10.1001/Jamaoncol.2014.161 |
0.3 |
|
| 2015 |
Hutchinson KE, Johnson DB, Johnson AS, Sanchez V, Kuba M, Lu P, Chen X, Kelley MC, Wang Q, Zhao Z, Kris M, Berger MF, Sosman JA, Pao W. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget. PMID 26084293 DOI: 10.18632/Oncotarget.4255 |
0.441 |
|
| 2015 |
Kawabata S, Hollander MC, Munasinghe JP, Brinster LR, Mercado-Matos JR, Li J, Regales L, Pao W, Jänne PA, Wong KK, Butman JA, Lonser RR, Hansen MR, Gurgel RK, Vortmeyer AO, et al. Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone. Oncotarget. 6: 11357-68. PMID 26027747 DOI: 10.18632/Oncotarget.3605 |
0.474 |
|
| 2015 |
Galvani E, Sun J, Leon LG, Sciarrillo R, Narayan RS, Tjin Tham Sjin R, Lee K, Ohashi K, Heideman DA, Alfieri RR, Heynen GJ, Bernards R, Smit EF, Pao W, Peters GJ, et al. NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor. Oncotarget. PMID 26015408 DOI: 10.18632/Oncotarget.3956 |
0.563 |
|
| 2015 |
Eberlein CA, Stetson D, Markovets AA, Al-Kadhimi KJ, Lai Z, Fisher PR, Meador CB, Spitzler P, Ichihara E, Ross SJ, Ahdesmaki MJ, Ahmed A, Ratcliffe LE, O'Brien EL, Barnes CH, ... ... Pao W, et al. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. Cancer Research. 75: 2489-500. PMID 25870145 DOI: 10.1158/0008-5472.Can-14-3167 |
0.533 |
|
| 2015 |
Meador CB, Pao W. Old Habits Die Hard: Addiction of BRAF-Mutant Cancer Cells to MAP Kinase Signaling. Cancer Discovery. 5: 348-50. PMID 25847954 DOI: 10.1158/2159-8290.Cd-15-0221 |
0.432 |
|
| 2015 |
Machiela MJ, Hsiung CA, Shu XO, Seow WJ, Wang Z, Matsuo K, Hong YC, Seow A, Wu C, Hosgood HD, Chen K, Wang JC, Wen W, Cawthon R, Chatterjee N, ... ... Pao W, et al. Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: a report from the female lung cancer consortium in Asia. International Journal of Cancer. Journal International Du Cancer. 137: 311-9. PMID 25516442 DOI: 10.1002/Ijc.29393 |
0.378 |
|
| 2015 |
Meador CB, Jin H, de Stanchina E, Nebhan CA, Pirazzoli V, Wang L, Lu P, Vuong H, Hutchinson KE, Jia P, Chen X, Eisenberg R, Ladanyi M, Politi K, Zhao Z, ... ... Pao W, et al. Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer. Molecular Cancer Therapeutics. 14: 542-52. PMID 25477325 DOI: 10.1158/1535-7163.Mct-14-0723 |
0.544 |
|
| 2015 |
Chan E, Goff LW, Cardin DB, Berlin J, Levy MA, Vnencak-Jones CL, Pao W. Routine multiplexed mutational analysis of colorectal cancers (CRCs): A single-institution experience. Journal of Clinical Oncology. 33: 599-599. DOI: 10.1200/Jco.2015.33.3_Suppl.599 |
0.461 |
|
| 2015 |
Yu HA, Sima CS, Reales D, Jordan S, Rudin CM, Kris MG, Michor F, Pao W, Riely GJ. A phase I study of twice weekly pulse dose and daily low dose erlotinib as initial treatment for patients (pts) with EGFR-mutant lung cancers. Journal of Clinical Oncology. 33: 8017-8017. DOI: 10.1200/Jco.2015.33.15_Suppl.8017 |
0.394 |
|
| 2015 |
Eberlein C, Al-Kadhimi K, Ross S, Brown H, Fisher P, Stetson D, Lai Z, Thress K, Dougherty B, Pao W, Cross D. Abstract PR05: ERK pathway activation is associated with acquired resistance to AZD9291, a third-generation irreversible inhibitor targeting EGFR sensitizing (EGFRm+) and resistance (T790M) mutations in NSCLC Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-Pr05 |
0.545 |
|
| 2015 |
Mumenthaler S, Foo J, Choi N, Pao W, Agus D, Michor F, Mallick P. Abstract PR16: Spatio-temporal heterogeneity in the tumor microenvironment influences the evolutionary dynamics of drug resistance Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-Pr16 |
0.392 |
|
| 2015 |
Ichihara E, Bauer JA, Lu P, Ye F, Cross D, Pao W, Lovly CM. Abstract 768: A kinome-wide siRNA screen identifies modifiers of sensitivity to the EGFR T790M-targeted tyrosine kinase inhibitor (TKI), AZD9291, in EGFR mutant lung adenocarcinoma Cancer Research. 75: 768-768. DOI: 10.1158/1538-7445.Am2015-768 |
0.532 |
|
| 2015 |
Ortiz-Cuarán S, Fernandez-Cuesta L, Lovly CM, Bos M, Scheffler M, Michels S, Albus K, Meyer L, König K, Dahmen I, Mueller C, Ozretić L, Tharun L, Schaub P, Florin A, ... ... Pao W, et al. Abstract 752: Elucidating the mechanisms of acquired resistance in lung adenocarcinomas Cancer Research. 75: 752-752. DOI: 10.1158/1538-7445.Am2015-752 |
0.571 |
|
| 2014 |
Cross D, D'Cruz C, Eberlein C, Spitzler P, Ichihara E, Meador C, Ashton S, Mellor M, Stewart R, Smith P, Schuller A, Frigault M, Pao W, Jewsbury PJ. 466PTARGETING RESISTANCE IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC): PRECLINICAL EVIDENCE SUPPORTING THE COMBINATION OF EGFR TYROSINE KINASE INHIBITORS (TKIS) AZD9291 AND GEFITINIB WITH MOLECULARLY TARGETED AGENTS AND IMMUNOTHERAPEUTICS. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv155. PMID 28172000 DOI: 10.1093/Annonc/Mdu331.26 |
0.563 |
|
| 2014 |
Ramalingam SS, Ohe Y, Nogami N, Yang JC, Eberlein C, Ashton S, Mellor M, Spitzler P, Meador C, Ichihara E, Cross D, Pao W, Ballard P, Hughes G, Cantarini M, et al. 454PPRE-CLINICAL AND CLINICAL EVALUATION OF AZD9291, A MUTATION-SPECIFIC INHIBITOR, IN TREATMENT-NAïVE EGFR MUTATED NSCLC. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv151. PMID 28170790 DOI: 10.1093/Annonc/Mdu331.14 |
0.483 |
|
| 2014 |
Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch KD, Chen J, Robinson HE, Shim HS, Chmielecki J, Pao W, Engelman JA, Iafrate AJ, Le LP. Anchored multiplex PCR for targeted next-generation sequencing. Nature Medicine. 20: 1479-84. PMID 25384085 DOI: 10.1038/Nm.3729 |
0.595 |
|
| 2014 |
Jia P, Wang Q, Chen Q, Hutchinson KE, Pao W, Zhao Z. MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis. Genome Biology. 15: 489. PMID 25348067 DOI: 10.1186/S13059-014-0489-9 |
0.427 |
|
| 2014 |
Chmielecki J, Hutchinson KE, Frampton GM, Chalmers ZR, Johnson A, Shi C, Elvin J, Ali SM, Ross JS, Basturk O, Balasubramanian S, Lipson D, Yelensky R, Pao W, Miller VA, et al. Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. Cancer Discovery. 4: 1398-405. PMID 25266736 DOI: 10.1158/2159-8290.Cd-14-0617 |
0.613 |
|
| 2014 |
Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretić L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, ... ... Pao W, et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nature Medicine. 20: 1027-34. PMID 25173427 DOI: 10.1038/Nm.3667 |
0.422 |
|
| 2014 |
Janjigian YY, Smit EF, Groen HJ, Horn L, Gettinger S, Camidge DR, Riely GJ, Wang B, Fu Y, Chand VK, Miller VA, Pao W. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discovery. 4: 1036-45. PMID 25074459 DOI: 10.1158/2159-8290.Cd-14-0326 |
0.599 |
|
| 2014 |
Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nature Reviews. Clinical Oncology. 11: 473-81. PMID 24981256 DOI: 10.1038/Nrclinonc.2014.104 |
0.501 |
|
| 2014 |
Kawabata S, Mercado-Matos JR, Hollander MC, Donahue D, Wilson W, Regales L, Butaney M, Pao W, Wong KK, Jänne PA, Dennis PA. Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. Cell Reports. 7: 1824-32. PMID 24931608 DOI: 10.1016/J.Celrep.2014.05.039 |
0.61 |
|
| 2014 |
Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, ... ... Pao W, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discovery. 4: 1046-61. PMID 24893891 DOI: 10.1158/2159-8290.Cd-14-0337 |
0.594 |
|
| 2014 |
Wang R, Wang L, Li Y, Hu H, Shen L, Shen X, Pan Y, Ye T, Zhang Y, Luo X, Zhang Y, Pan B, Li B, Li H, Zhang J, ... Pao W, et al. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4107-14. PMID 24850843 DOI: 10.1158/1078-0432.Ccr-14-0284 |
0.52 |
|
| 2014 |
Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, ... ... Pao W, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. Jama. 311: 1998-2006. PMID 24846037 DOI: 10.1001/Jama.2014.3741 |
0.481 |
|
| 2014 |
Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, Zhao Z, Jia P, de Stanchina E, Shapiro EM, Gale M, Yin R, Horn L, Carbone DP, Stephens PJ, ... ... Pao W, et al. Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell Reports. 7: 999-1008. PMID 24813888 DOI: 10.1016/J.Celrep.2014.04.014 |
0.484 |
|
| 2014 |
Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, ... ... Pao W, et al. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. The Oncologist. 19: 616-22. PMID 24797823 DOI: 10.1200/Jco.2014.32.15_Suppl.11089 |
0.376 |
|
| 2014 |
Xia J, Jia P, Hutchinson KE, Dahlman KB, Johnson D, Sosman J, Pao W, Zhao Z. A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Molecular Cancer Therapeutics. 13: 1918-28. PMID 24755198 DOI: 10.1158/1535-7163.Mct-13-0804 |
0.435 |
|
| 2014 |
Abramson VG, Cooper Lloyd M, Ballinger T, Sanders ME, Du L, Lai D, Su Z, Mayer I, Levy M, LaFrance DR, Vnencak-Jones CL, Shyr Y, Dahlman KB, Pao W, Arteaga CL. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Research and Treatment. 145: 389-99. PMID 24722917 DOI: 10.1007/S10549-014-2945-3 |
0.453 |
|
| 2014 |
Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2264-75. PMID 24599935 DOI: 10.1158/1078-0432.Ccr-13-1591 |
0.393 |
|
| 2014 |
Jia P, Pao W, Zhao Z. Patterns and processes of somatic mutations in nine major cancers. Bmc Medical Genomics. 7: 11. PMID 24552141 DOI: 10.1186/1755-8794-7-11 |
0.436 |
|
| 2014 |
Wang R, Pan Y, Li C, Zhang H, Garfield D, Li Y, Ye T, Hu H, Luo X, Li H, Zhang Y, Zhang J, Zhou X, Shen L, Pao W, et al. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 760-8. PMID 24481316 DOI: 10.1097/Jto.0B013E3182A406D1 |
0.5 |
|
| 2014 |
Wang Z, Sun Y, Gao B, Lu Y, Fang R, Gao Y, Xiao T, Liu XY, Pao W, Zhao Y, Chen H, Ji H. Two co-existing germline mutations P53 V157D and PMS2 R20Q promote tumorigenesis in a familial cancer syndrome. Cancer Letters. 342: 36-42. PMID 23981578 DOI: 10.1016/J.Canlet.2013.08.032 |
0.452 |
|
| 2014 |
Horn L, Infante JR, Blumenschein GR, Wakelee HA, Arkenau H, Dukart G, Liang C, Harrow K, Gibbons J, Lovly CM, Pao W. A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology. 32: 8030-8030. DOI: 10.1200/Jco.2014.32.15_Suppl.8030 |
0.418 |
|
| 2014 |
Miller VA, Chmielecki J, Hutchinson K, Frampton GM, Ali SM, Ross JS, Shi C, Pao W, Klimstra DS, Yelensky R, Lipson D, Stephens P. Next-generation sequencing (NGS)-based profiling of pancreatic acinar cell carcinoma for identification of a recurrent SND1-BRAF fusion. Journal of Clinical Oncology. 32: 11029-11029. DOI: 10.1200/Jco.2014.32.15_Suppl.11029 |
0.61 |
|
| 2014 |
Ortiz-Cuarán S, Fernandez-Cuesta L, Bos M, Heukamp L, Lovly CM, Peifer M, Gardizi M, Scheffler M, Dahmen I, Müller C, König K, Albus K, Florin A, Ansén S, Buettner R, ... ... Pao W, et al. Abstract 956: Elucidating the mechanisms of acquired resistance in lung adenocarcinomas Cancer Research. 74: 956-956. DOI: 10.1158/1538-7445.Am2014-956 |
0.588 |
|
| 2014 |
Eberlein C, Ratcliffe L, O'Brien L, Al-Khadimi K, Brown H, Fisher P, Stetson D, Lai Z, Marshall G, Barnes C, Thress K, Dougherty B, Pao W, Cross D. Abstract 1722: Investigating resistance to AZD9291 Cancer Research. 74: 1722-1722. DOI: 10.1158/1538-7445.Am2014-1722 |
0.527 |
|
| 2014 |
Meador CB, Jin H, Stanchina Ed, Pirazzoli V, Ladanyi M, Wang L, Chen X, Eisenberg R, Cross D, Pao W. Abstract B10: Acquired resistance to afatinib plus cetuximab in EGFR-mutant lung adenocarcinoma may be mediated by EGFR overexpression and overcome by the mutant-specific EGFR inhibitor, AZD9291. Clinical Cancer Research. 20: B10-B10. DOI: 10.1158/1078-0432.14Aacriaslc-B10 |
0.591 |
|
| 2013 |
Sanders M, Kuba MG, Farley J, Lai D, Su Z, Mayer IA, Means-Powell JA, Vnenzak-Jones C, Levy MA, Pao W, Arteaga CL, Abramson VG. Clinical and pathologic characteristics of patients with PI3K-mutant breast cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 8. PMID 28136604 DOI: 10.1200/Jco.2013.31.26_Suppl.8 |
0.399 |
|
| 2013 |
Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, Vnencak-Jones CL, Ross JS, Pietenpol JA, Sosman JA, Puzanov I, Miller VA, Pao W. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6696-702. PMID 24345920 DOI: 10.1158/1078-0432.Ccr-13-1746 |
0.406 |
|
| 2013 |
Seidel D, Zander T, Heukamp LC, Peifer M, Bos M, Fernandez-Cuesta L, Leenders F, Lu X, Ansen S, Gardizi M, Nguyen C, Berg J, Russell P, Wainer Z, Schildhaus H, ... ... Pao W, et al. A genomics-based classification of human lung tumors Science Translational Medicine. 5. PMID 24174329 DOI: 10.1126/Scitranslmed.3006802 |
0.454 |
|
| 2013 |
Wang Q, Jia P, Li F, Chen H, Ji H, Hucks D, Dahlman KB, Pao W, Zhao Z. Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. Genome Medicine. 5: 91. PMID 24112718 DOI: 10.1186/Gm495 |
0.426 |
|
| 2013 |
Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, Sheets M, St Martin T, Karp R, van Kalken D, Chaturvedi P, ... ... Pao W, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discovery. 3: 1404-15. PMID 24065731 DOI: 10.1158/2159-8290.Cd-13-0314 |
0.599 |
|
| 2013 |
Hosgood HD, Pao W, Rothman N, Hu W, Pan YH, Kuchinsky K, Jones KD, Xu J, Vermeulen R, Simko J, Lan Q. Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning. Respiratory Medicine. 107: 1755-62. PMID 24055406 DOI: 10.1016/J.Rmed.2013.08.018 |
0.531 |
|
| 2013 |
Red Brewer M, Yun CH, Lai D, Lemmon MA, Eck MJ, Pao W. Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 110: E3595-604. PMID 24019492 DOI: 10.1073/Pnas.1220050110 |
0.532 |
|
| 2013 |
Yu HA, Pao W. Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer. Nature Reviews. Clinical Oncology. 10: 551-2. PMID 23959269 DOI: 10.1038/Nrclinonc.2013.154 |
0.563 |
|
| 2013 |
Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, Michor F, Zhao Z, Pao W. Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Research. 23: 1434-45. PMID 23733853 DOI: 10.1101/Gr.152322.112 |
0.51 |
|
| 2013 |
Nebhan C, Pao W. Further advances in genetically informed lung cancer medicine. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 521-2. PMID 23584291 DOI: 10.1097/Jto.0B013E31828F583C |
0.618 |
|
| 2013 |
Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, ... ... Pao W, et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2584-91. PMID 23515407 DOI: 10.1158/1078-0432.Ccr-12-3173 |
0.527 |
|
| 2013 |
Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2240-7. PMID 23470965 DOI: 10.1158/1078-0432.Ccr-12-2246 |
0.579 |
|
| 2013 |
Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1070-80. PMID 23401451 DOI: 10.1200/Jco.2012.43.3912 |
0.514 |
|
| 2013 |
Red Brewer M, Pao W. Maximizing the benefits of off-target kinase inhibitor activity. Cancer Discovery. 3: 138-40. PMID 23400472 DOI: 10.1158/2159-8290.Cd-12-0581 |
0.518 |
|
| 2013 |
Yeh P, Chen H, Andrews J, Naser R, Pao W, Horn L. DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1894-901. PMID 23344264 DOI: 10.1158/1078-0432.Ccr-12-1894 |
0.513 |
|
| 2013 |
Wang Q, Xia J, Jia P, Pao W, Zhao Z. Application of next generation sequencing to human gene fusion detection: computational tools, features and perspectives. Briefings in Bioinformatics. 14: 506-19. PMID 22877769 DOI: 10.1093/Bib/Bbs044 |
0.32 |
|
| 2013 |
Johnson ML, Sima CS, Chaft J, Paik PK, Pao W, Kris MG, Ladanyi M, Riely GJ. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer. 119: 356-62. PMID 22810899 DOI: 10.1002/Cncr.27730 |
0.548 |
|
| 2013 |
Kris MG, Oxnard GR, Johnson BE, Berry LD, Chen H, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Franklin WA, Aisner D, Sequist LV, Khuri FR, Garon EB, Pao W, Rudin CM, et al. Incidence, characteristics, and survival of patients with EGFR-mutant lung cancers with EGFR T790M at diagnosis identified in the lung cancer mutation consortium (LCMC). Journal of Clinical Oncology. 31: 8085-8085. DOI: 10.1200/Jco.2013.31.15_Suppl.8085 |
0.579 |
|
| 2013 |
Johnson BE, Kris MG, Berry LD, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M, Wistuba II, Franklin WA, Ladanyi M, Su P, Sequist LV, Khuri FR, Garon EB, Pao W, Rudin CM, et al. A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC). Journal of Clinical Oncology. 31: 8019-8019. DOI: 10.1200/Jco.2013.31.15_Suppl.8019 |
0.52 |
|
| 2013 |
Pirazzoli V, Stanchina Ed, Xia J, Zhao Z, Pao W, Politi KA. Abstract 933: Modeling acquired resistance to EGFR-directed therapies in mouse models of lung cancer. Cancer Research. 73: 933-933. DOI: 10.1158/1538-7445.Am2013-933 |
0.561 |
|
| 2013 |
Meador C, Ohashi K, Pan Y, Stanchina Ed, Pedersen MW, Horak I, Kragh M, Pao W. Abstract 2438: Mechanisms of sensitivity and resistance to Sym004, a novel anti-EGFR antibody mixture, in EGFR mutant lung cancer. Cancer Research. 73: 2438-2438. DOI: 10.1158/1538-7445.Am2013-2438 |
0.579 |
|
| 2013 |
Ohashi K, Suda K, Sun J, Pan Y, Walter AO, Dubrovskiy A, Tjin R, Mitsudomi T, Pao W. Abstract 2101A: CNX-2006, a novel irreversible epidermal growth factor receptor (EGFR) inhibitor, selectively inhibits EGFR T790M and fails to induce T790M-mediated resistancein vitro. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-2101A |
0.566 |
|
| 2013 |
Brewer MLR, Lai D, Lemmon MA, Pao W. Abstract 1106: Mechanism for activation of mutated EGF receptors in lung cancer. Cancer Research. 73: 1106-1106. DOI: 10.1158/1538-7445.Am2013-1106 |
0.586 |
|
| 2013 |
Hutchinson K, Lipson D, Stephens PJ, Otto G, Lyle PL, Vnencak-Jones CL, Ross JS, Sosman JA, Puzanov I, Miller VA, Pao W. Abstract PR04: BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-Pr04 |
0.467 |
|
| 2013 |
Pirazzoli V, Nebhan C, Song X, Walter Z, Cai G, Wurtz A, Zhao Z, Stanchina EEd, Horn L, Carbone D, Stevens PJ, Miller V, Gettinger S, Pao W, Politi K. Abstract C90: Dependence of afatinib and cetuximab resistant lung adenocarcinomas on mTOR signaling. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C90 |
0.593 |
|
| 2013 |
Cross D, Ashton S, Nebhan C, Eberlein C, Finlay MRV, Hughes G, Jacobs V, Mellor M, Brewer MR, Meador C, Orme J, Spitzler P, Powell S, Rahi A, Taylor P, ... ... Pao W, et al. Abstract A109: AZD9291: an irreversible, potent and selective third generation tyrosine kinase inhibitor (TKI) targeting EGFR activating (EGFRm+) and resistance (T790M) mutations in advanced lung adenocarcinoma. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A109 |
0.595 |
|
| 2013 |
Brewer MR, Yun CH, Lai D, Lemmon MA, Eck MJ, Pao W. Mechanism for activation of mutated epidermal growth factor receptors in lung cancer (Proceedings of the National Academy of Sciences of the United States of America (2013) 110, 38 (E3595-E3604) DOI: 10.1073/pnas.1220050110) Proceedings of the National Academy of Sciences of the United States of America. 110: 20344. DOI: 10.1073/pnas.1320849110 |
0.333 |
|
| 2012 |
Wang R, Hu H, Pan Y, Li Y, Ye T, Li C, Luo X, Wang L, Li H, Zhang Y, Li F, Lu Y, Lu Q, Xu J, Garfield D, ... ... Pao W, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 4352-9. PMID 23150706 DOI: 10.1200/Jco.2012.44.1477 |
0.515 |
|
| 2012 |
Lan Q, Hsiung CA, Matsuo K, Hong YC, Seow A, Wang Z, Hosgood HD, Chen K, Wang JC, Chatterjee N, Hu W, Wong MP, Zheng W, Caporaso N, Park JY, ... ... Pao W, et al. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nature Genetics. 44: 1330-5. PMID 23143601 DOI: 10.1038/Ng.2456 |
0.358 |
|
| 2012 |
Levy MA, Lovly CM, Pao W. Translating genomic information into clinical medicine: lung cancer as a paradigm. Genome Research. 22: 2101-8. PMID 23019146 DOI: 10.1101/Gr.131128.111 |
0.405 |
|
| 2012 |
Foo J, Chmielecki J, Pao W, Michor F. Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 1583-93. PMID 22982659 DOI: 10.1097/Jto.0B013E31826146Ee |
0.74 |
|
| 2012 |
Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, ... ... Pao W, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 150: 1107-20. PMID 22980975 DOI: 10.1016/J.Cell.2012.08.029 |
0.535 |
|
| 2012 |
Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, Riely GJ, Kris MG, Miller VA, Ladanyi M, Politi K, ... Pao W, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discovery. 2: 922-33. PMID 22956644 DOI: 10.1158/2159-8290.Cd-12-0108 |
0.586 |
|
| 2012 |
Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, ... ... Pao W, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics. 44: 1104-10. PMID 22941188 DOI: 10.1038/Ng.2396 |
0.529 |
|
| 2012 |
Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, Koker M, Meder L, Lovly CM, Heukamp LC, Pao W, Küppers R, Thomas RK. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4682-90. PMID 22912387 DOI: 10.1158/1078-0432.Ccr-11-3260 |
0.465 |
|
| 2012 |
Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, Atefi M, Su Z, Branch S, Lyle PL, Hicks DJ, Bozon V, Glaspy JA, Rosen N, Solit DB, ... ... Pao W, et al. BRAFL597 mutations in melanoma are associated with sensitivity to MEK inhibitors Cancer Discovery. 2: 791-797. PMID 22798288 DOI: 10.1158/2159-8290.Cd-12-0097 |
0.46 |
|
| 2012 |
Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, ... ... Pao W, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proceedings of the National Academy of Sciences of the United States of America. 109: E2127-33. PMID 22773810 DOI: 10.1073/Pnas.1203530109 |
0.748 |
|
| 2012 |
Yatabe Y, Pao W, Jett JR. Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 775-6. PMID 22722783 DOI: 10.1097/Jto.0B013E318251980B |
0.557 |
|
| 2012 |
Oxnard GR, Miller VA, Robson ME, Azzoli CG, Pao W, Ladanyi M, Arcila ME. Screening for germline EGFR T790M mutations through lung cancer genotyping. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 1049-52. PMID 22588155 DOI: 10.1097/Jto.0B013E318250Ed9D |
0.572 |
|
| 2012 |
Pao W. New approaches to targeted therapy in lung cancer. Proceedings of the American Thoracic Society. 9: 72-3. PMID 22550248 DOI: 10.1513/pats.201112-054MS |
0.353 |
|
| 2012 |
Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, ... ... Pao W, et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. Plos One. 7: e35309. PMID 22536370 DOI: 10.1371/Journal.Pone.0035309 |
0.465 |
|
| 2012 |
Xia J, Wang Q, Jia P, Wang B, Pao W, Zhao Z. NGS catalog: A database of next generation sequencing studies in humans. Human Mutation. 33: E2341-55. PMID 22517761 DOI: 10.1002/Humu.22096 |
0.303 |
|
| 2012 |
Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nature Medicine. 18: 349-51. PMID 22395697 DOI: 10.1038/Nm.2697 |
0.523 |
|
| 2012 |
Lovly CM, Pao W. Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Science Translational Medicine. 4: 120ps2. PMID 22323827 DOI: 10.1126/Scitranslmed.3003728 |
0.458 |
|
| 2012 |
Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y, Luo X, Ye T, Wang R, Hu H, Li H, Wang L, Pao W, Chen H. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1947-53. PMID 22317764 DOI: 10.1158/1078-0432.Ccr-11-2511 |
0.503 |
|
| 2012 |
Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, ... ... Pao W, et al. ROS1 rearrangements define a unique molecular class of lung cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 863-70. PMID 22215748 DOI: 10.1200/Jco.2011.35.6345 |
0.519 |
|
| 2012 |
Chmielecki J, Pietanza MC, Aftab D, Shen R, Zhao Z, Chen X, Hutchinson K, Viale A, Kris MG, Stout T, Miller V, Rizvi N, Pao W. EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 434-42. PMID 22173702 DOI: 10.1097/Jto.0B013E31823C5Aee |
0.732 |
|
| 2012 |
Li C, Sun Y, Fang R, Han X, Luo X, Wang R, Pan Y, Hu H, Zhang Y, Pao W, Shen L, Ji H, Chen H. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 85-9. PMID 22071781 DOI: 10.1097/Jto.0B013E318234F0A2 |
0.543 |
|
| 2012 |
Chmielecki J, Peifer M, Viale A, Hutchinson K, Giltnane J, Socci ND, Hollis CJ, Dean RS, Yenamandra A, Jagasia M, Kim AS, Davé UP, Thomas RK, Pao W. Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. Genes, Chromosomes & Cancer. 51: 54-65. PMID 21938754 DOI: 10.1002/Gcc.20930 |
0.624 |
|
| 2012 |
Gong Y, Pao W. EGFR mutant lung cancer. Current Topics in Microbiology and Immunology. 355: 59-81. PMID 21866438 DOI: 10.1007/82_2011_171 |
0.603 |
|
| 2012 |
Girard N, Sima CS, Jackman DM, Sequist LV, Chen H, Yang JCH, Ji H, Waltman B, Rosell R, Taron M, Zakowski MF, Ladanyi M, Riely G, Pao W. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma European Respiratory Journal. 39: 366-372. PMID 21778168 DOI: 10.1183/09031936.00010111 |
0.54 |
|
| 2012 |
Varella-Garcia M, Berry LD, Su P, Franklin WA, Iafrate AJ, Ladanyi M, Camidge DR, Garon EB, Haura EB, Horn L, Khuri FR, Pao W, Rudin CM, Shaw AT, Schiller JH, et al. ALK and MET genes in advanced lung adenocarcinomas: The Lung Cancer Mutation Consortium experience. Journal of Clinical Oncology. 30: 7589-7589. DOI: 10.1200/Jco.2012.30.15_Suppl.7589 |
0.478 |
|
| 2012 |
Horn L, Li C, Pao W, Keedy VL, Johnson DH, Carbone DP. A phase II study of erlotinib followed by chemotherapy on progression in an unselected population of advanced non-small cell lung cancer (NSCLC) patients. Journal of Clinical Oncology. 30: 7568-7568. DOI: 10.1200/Jco.2012.30.15_Suppl.7568 |
0.449 |
|
| 2012 |
Ohashi K, Sequist LV, Sos M, Chen X, Rudin CM, Moran T, Arcila ME, Lovly CM, Vnencak-Jones CL, Sasaki H, Dias-Santagata D, Dubinett SM, Riely GJ, Ladanyi M, Franklin WA, ... ... Pao W, et al. Characteristics of NSCLCs harboring NRAS mutations. Journal of Clinical Oncology. 30: 7532-7532. DOI: 10.1200/Jco.2012.30.15_Suppl.7532 |
0.556 |
|
| 2012 |
Lammers PE, Matthews-Smith V, Yun Y, Pan Y, Zaja-Milatovic S, Sullivan A, Eisenberg R, Gonzalez A, Shyr Y, Wolff SN, Schwartz AG, Pao W, Carbone DP. Somatic mutation spectrum of non-small cell lung cancers (NSCLCs) from African Americans (AAs). Journal of Clinical Oncology. 30: 6038-6038. DOI: 10.1200/Jco.2012.30.15_Suppl.6038 |
0.517 |
|
| 2012 |
Hosgood HD, Pao W, Rothman N, Wei H, Kim C, Pan H, Kuchinsky K, Jones K, Xu J, Vermeulen R, Simko J, Lan Q. Abstract 5479: Somatic driver mutations among never smoking female lung cancer cases in China identify unique mutation pattern that may be associated with household coal burning Cancer Research. 72: 5479-5479. DOI: 10.1158/1538-7445.Am2012-5479 |
0.542 |
|
| 2012 |
Dahlman KB, Xia J, Hutchinson K, Hucks D, Jia P, Su Z, Hicks DJ, Netterville JL, Vnencak-Jones CL, Sosman J, Zhao Z, Pao W. Abstract 5102: Identifying targets for melanoma therapy: Biological and clinical implications of BRAF L597 mutants Cancer Research. 72: 5102-5102. DOI: 10.1158/1538-7445.Am2012-5102 |
0.451 |
|
| 2012 |
Ohashi K, Chmielecki J, Lin Y, Pan H, Vnencak-Jones C, Arcila M, Wang L, Fernandez L, Keisuke A, Shien K, Yamamoto H, Toyooka S, Kiura K, Thomas R, Yang JC, ... ... Pao W, et al. Abstract 1897: RAS signaling pathway gene mutations and acquired resistance to EGFR tyrosine-kinase inhibitors in EGFR mutant lung cancer Cancer Research. 72: 1897-1897. DOI: 10.1158/1538-7445.Am2012-1897 |
0.742 |
|
| 2012 |
Pirazzoli V, Takezawa K, de Stanchina E, Pao W, Politi K. Abstract A38: Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas Clinical Cancer Research. 18: A38-A38. DOI: 10.1158/1078-0432.Mechres-A38 |
0.528 |
|
| 2012 |
Takezawa K, Melnick MA, Riely G, Kris M, Miller V, Ladanyi M, Politi K, Pao W, Pirazzoli V, Song X, Arcila M, De Stanchina E, Ohashi K, Janjigian Y, Spitzler P, et al. Abstract A23: HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer Clinical Cancer Research. 18: A23-A23. DOI: 10.1158/1078-0432.Mechres-A23 |
0.574 |
|
| 2012 |
Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, ... ... Pao W, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer (Science Translational Medicine (2012) 4, (130er2)) Science Translational Medicine. 4. DOI: 10.1126/Scitranslmed.3002121 |
0.44 |
|
| 2012 |
Janjigian YY, Smit EF, Horn L, Groen H, Camidge DR, Gettinger S, Fu Y, Denis LJ, Miller V, Pao W. Activity Of Afatinib/Cetuximab In Patients (Pts) With Egfr Mutant Non-Small Cell Lung Cancer (Nsclc) And Acquired Resistance (Ar) To Egfr Inhibitors Annals of Oncology. 23: 401-401. DOI: 10.1016/S0923-7534(20)33838-2 |
0.49 |
|
| 2012 |
Girard N, Sima C, Jackman D, Sequist L, Chen H, Yang J, Bi H, Waltman B, Rosell R, Taron M, Zakowski M, Ladanyi M, Riely G, Pao W. Nomogramme prédictif des mutations activatrices de l’EGFR dans les adénocarcinomes pulmonaires Revue Des Maladies Respiratoires. 29: A44-A45. DOI: 10.1016/J.Rmr.2011.10.088 |
0.344 |
|
| 2011 |
Lovly CM, de Stanchina E, Chen H, Liang C, Pao W. Characterization of novel potent and selective anaplastic lymphoma kinase (ALK) inhibitors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e13600. PMID 28023522 DOI: 10.1200/Jco.2011.29.15_Suppl.E13600 |
0.484 |
|
| 2011 |
Janjigian YY, Groen HJ, Horn L, Smit EF, Fu Y, Wang F, Shahidi M, Denis LJ, Pao W, Miller VA. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7525. PMID 28023254 DOI: 10.1200/Jco.2011.29.15_Suppl.7525 |
0.522 |
|
| 2011 |
Horn L, Chen H, Lovly CM, Andrews J, Yeh P, Levy MA, Pao W. DIRECT: DNA-mutation Inventory to Refine and Enhance Cancer Treatment-A catalogue of clinically relevant somatic mutations in lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7575. PMID 28023127 DOI: 10.1200/Jco.2011.29.15_Suppl.7575 |
0.557 |
|
| 2011 |
Levy MA, Lovly CM, Horn L, Naser R, Pao W. My Cancer Genome: Web-based clinical decision support for genome-directed lung cancer treatment. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7576. PMID 28023120 DOI: 10.1200/Jco.2011.29.15_Suppl.7576 |
0.515 |
|
| 2011 |
Kris MG, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Aronson SL, Engelman JA, Shyr Y, Khuri FR, Rudin CM, Garon EB, Pao W, Schiller JH, Haura EB, Shirai K, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: CRA7506. PMID 28020340 DOI: 10.1200/jco.2011.29.15_suppl.cra7506 |
0.417 |
|
| 2011 |
Kris MG, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Aronson SL, Engelman JA, Shyr Y, Khuri FR, Rudin CM, Garon EB, Pao W, Schiller JH, Haura EB, Shirai K, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: CRA7506. PMID 27937162 DOI: 10.1200/jco.2011.29.18_suppl.cra7506 |
0.443 |
|
| 2011 |
Ohashi K, Pao W. A new target for therapy in squamous cell carcinoma of the lung. Cancer Discovery. 1: 23-4. PMID 22586316 DOI: 10.1158/2159-8274.Cd-11-0069 |
0.52 |
|
| 2011 |
Li C, Fang R, Sun Y, Han X, Li F, Gao B, Iafrate AJ, Liu XY, Pao W, Chen H, Ji H. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. Plos One. 6: e28204. PMID 22140546 DOI: 10.1371/Journal.Pone.0028204 |
0.531 |
|
| 2011 |
Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 9: S1-32; quiz S33. PMID 22138009 DOI: 10.6004/Jnccn.2011.0137 |
0.345 |
|
| 2011 |
Mumenthaler SM, Foo J, Leder K, Choi NC, Agus DB, Pao W, Mallick P, Michor F. Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Molecular Pharmaceutics. 8: 2069-79. PMID 21995722 DOI: 10.1021/Mp200270V |
0.487 |
|
| 2011 |
Heuckmann JM, Hölzel M, Sos ML, Heynck S, Balke-Want H, Koker M, Peifer M, Weiss J, Lovly CM, Grütter C, Rauh D, Pao W, Thomas RK. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7394-401. PMID 21948233 DOI: 10.1158/1078-0432.Ccr-11-1648 |
0.513 |
|
| 2011 |
Azzoli CG, Temin S, Aliff T, Baker S, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pao W, Pfister DG, Piantadosi S, Schiller JH, Smith R, et al. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3825-31. PMID 21900105 DOI: 10.1200/Jco.2010.34.2774 |
0.412 |
|
| 2011 |
Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, Clarke JL, Lassman AB. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro-Oncology. 13: 1364-9. PMID 21865399 DOI: 10.1093/Neuonc/Nor121 |
0.559 |
|
| 2011 |
Riely GJ, Johnson ML, Medina C, Rizvi NA, Miller VA, Kris MG, Pietanza MC, Azzoli CG, Krug LM, Pao W, Ginsberg MS. A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1435-7. PMID 21847063 DOI: 10.1097/Jto.0B013E318223C099 |
0.449 |
|
| 2011 |
Oxnard GR, Janjigian YY, Arcila ME, Sima CS, Kass SL, Riely GJ, Pao W, Kris MG, Ladanyi M, Azzoli CG, Miller VA. Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib Clinical Cancer Research. 17: 6322-6328. PMID 21831955 DOI: 10.1158/1078-0432.Ccr-11-1080 |
0.582 |
|
| 2011 |
Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5530-7. PMID 21775534 DOI: 10.1158/1078-0432.Ccr-10-2571 |
0.741 |
|
| 2011 |
Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, Wang L, Amato KR, Arcila M, Sos ML, Socci ND, Viale A, de Stanchina E, Ginsberg MS, Thomas RK, ... ... Pao W, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Science Translational Medicine. 3: 90ra59. PMID 21734175 DOI: 10.1126/Scitranslmed.3002356 |
0.73 |
|
| 2011 |
Johnson ML, Riely GJ, Rizvi NA, Azzoli CG, Kris MG, Sima CS, Ginsberg MS, Pao W, Miller VA. Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1128-31. PMID 21623279 DOI: 10.1097/Jto.0B013E3182161508 |
0.57 |
|
| 2011 |
Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, Pao W. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Research. 71: 4920-31. PMID 21613408 DOI: 10.1158/0008-5472.Can-10-3879 |
0.438 |
|
| 2011 |
Rizvi NA, Rusch V, Pao W, Chaft JE, Ladanyi M, Miller VA, Krug LM, Azzoli CG, Bains M, Downey R, Flores R, Park B, Singh B, Zakowski M, Heelan RT, et al. Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3500-6. PMID 21558399 DOI: 10.1158/1078-0432.Ccr-10-2102 |
0.521 |
|
| 2011 |
Andrews J, Yeh P, Pao W, Horn L. Molecular predictors of response to chemotherapy in non-small cell lung cancer. Cancer Journal (Sudbury, Mass.). 17: 104-13. PMID 21427554 DOI: 10.1097/Ppo.0B013E318213F3Cf |
0.458 |
|
| 2011 |
Li J, Su Z, Ma ZQ, Slebos RJ, Halvey P, Tabb DL, Liebler DC, Pao W, Zhang B. A bioinformatics workflow for variant peptide detection in shotgun proteomics. Molecular & Cellular Proteomics : McP. 10: M110.006536. PMID 21389108 DOI: 10.1074/Mcp.M110.006536 |
0.324 |
|
| 2011 |
Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America. 108: 5021-6. PMID 21385943 DOI: 10.1073/Pnas.1016140108 |
0.408 |
|
| 2011 |
Pao W, Girard N. New driver mutations in non-small-cell lung cancer. The Lancet. Oncology. 12: 175-80. PMID 21277552 DOI: 10.1016/S1470-2045(10)70087-5 |
0.556 |
|
| 2011 |
Politi K, Pao W. How genetically engineered mouse tumor models provide insights into human cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2273-81. PMID 21263096 DOI: 10.1200/Jco.2010.30.8304 |
0.348 |
|
| 2011 |
Janjigian YY, Azzoli CG, Krug LM, Pereira LK, Rizvi NA, Pietanza MC, Kris MG, Ginsberg MS, Pao W, Miller VA, Riely GJ. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2521-7. PMID 21248303 DOI: 10.1158/1078-0432.Ccr-10-2662 |
0.542 |
|
| 2011 |
Arcila ME, Oxnard GR, Nafa K, Riely GJ, Solomon SB, Zakowski MF, Kris MG, Pao W, Miller VA, Ladanyi M. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1169-80. PMID 21248300 DOI: 10.1158/1078-0432.Ccr-10-2277 |
0.573 |
|
| 2011 |
Su Z, Dias-Santagata D, Duke M, Hutchinson K, Lin YL, Borger DR, Chung CH, Massion PP, Vnencak-Jones CL, Iafrate AJ, Pao W. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. The Journal of Molecular Diagnostics : Jmd. 13: 74-84. PMID 21227397 DOI: 10.1016/J.Jmoldx.2010.11.010 |
0.523 |
|
| 2011 |
Janjigian YY, Park BJ, Zakowski MF, Ladanyi M, Pao W, D'Angelo SP, Kris MG, Shen R, Zheng J, Azzoli CG. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 569-75. PMID 21150674 DOI: 10.1097/Jto.0B013E318202Bffe |
0.56 |
|
| 2011 |
Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, Pao W, Ladanyi M, Miller VA. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1616-22. PMID 21135146 DOI: 10.1158/1078-0432.Ccr-10-2692 |
0.741 |
|
| 2011 |
Pao W, Iafrate AJ, Su Z. Genetically informed lung cancer medicine. The Journal of Pathology. 223: 230-40. PMID 21125677 DOI: 10.1002/Path.2788 |
0.487 |
|
| 2011 |
Lovly CM, Li C, Hutchison AS, Carbone DP, Johnson DH, Keedy VL, Pao W, Sandler A, Horn L. A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC). Journal of Clinical Oncology. 29: 7094-7094. DOI: 10.1200/Jco.2012.30.15_Suppl.7094 |
0.367 |
|
| 2011 |
Chmielecki J, Peifer M, Viale A, Socci N, Jia P, Zhao Z, Thomas R, Pao W. Abstract LB-236: Identifying novel kinase fusions via targeted DNA capture and next-generation sequencing Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-236 |
0.674 |
|
| 2011 |
Hatakeyama H, Dahlman KB, Su Z, Robbert S, Pao W, Chung CH. Abstract 731: Nuclear factor-κB activation and cetuximab-resistance in HNSCC cell lines Cancer Research. 71: 731-731. DOI: 10.1158/1538-7445.Am2011-731 |
0.493 |
|
| 2011 |
Chmielecki J, Peifer M, Viale A, Hutchinson K, Giltnane J, Socci ND, Yenamandra A, Jagasia M, Kim AS, Dave U, Thomas RK, Pao W. Abstract 4977: Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables discovery of a novel C6orf204-PDGFRβ fusion in a patient with T-ALL and eosinophilia Cancer Research. 71: 4977-4977. DOI: 10.1158/1538-7445.Am2011-4977 |
0.611 |
|
| 2011 |
Gao SP, Mao N, Schori E, Liu S, Daly L, Barlas A, Gueorguiev VD, Zhao H, Qiu J, Hefter B, Regales L, Chmielecki J, Pao W, Bromberg JF. Abstract 4689: Inhibition of IL-6/Jak/Stat3 signaling: a novel and potent targeting therapy for lung cancer Cancer Research. 71: 4689-4689. DOI: 10.1158/1538-7445.Am2011-4689 |
0.693 |
|
| 2011 |
Kawabata S, Mercado J, Hollander MC, Wilson W, Regales L, Pao W, Janne PA, Wong K, Dennis PA. Abstract 2836: Rapamycin prolongs overall survival and progression-free survival in a mouse model of lung cancer in never smokers resistant to erlotinib Cancer Research. 71: 2836-2836. DOI: 10.1158/1538-7445.Am2011-2836 |
0.574 |
|
| 2011 |
Kawabata S, Hollander MC, Munasinghe JP, Mercado J, Brinster LR, Butman JA, Lonser RR, Regales L, Pao W, Janne PA, Wong K, Dennis PA. Abstract 2417: A new mouse model for epithelial ear neoplasms based upon expression of mutant EGFRL858R/T790M Cancer Research. 71: 2417-2417. DOI: 10.1158/1538-7445.Am2011-2417 |
0.519 |
|
| 2011 |
Garrett J, Rinehart C, Chakrabarty A, Dave B, Pao W, Manning C, Chang J, Arteaga C. Abstract 231: Upregulation of HER3 (ErbB3) levels and function counteracts the antitumor effect of HER2 and PI3K inhibitors Cancer Research. 71: 231-231. DOI: 10.1158/1538-7445.Am2011-231 |
0.414 |
|
| 2011 |
Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, ... ... Pao W, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer (Science Translational Medicine (2011) 3) Science Translational Medicine. 3. DOI: 10.1126/scitranslmed.3002121 |
0.341 |
|
| 2011 |
Johnson B, Kris M, Kwiatkowski D, Wistuba I, Engelman J, Pao W, Rudin C, Berry L, Minna J, Bunn P. 9018 POSTER DISCUSSION Identification of Driver Mutations in Tumour Specimens From 1000 Patients With Lung Adenocarcinoma for the Lung Cancer Mutation Consortium (LCMC) European Journal of Cancer. 47: S597. DOI: 10.1016/S0959-8049(11)72330-9 |
0.425 |
|
| 2010 |
Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, ... ... Pao W, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Translational Medicine. 2: 62ra93. PMID 21160078 DOI: 10.1126/Scitranslmed.3001451 |
0.541 |
|
| 2010 |
Chmielecki J, Pao W. Highly active antitumor therapy (HAATT) for epidermal growth factor receptor-mutant lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5371-3. PMID 21062927 DOI: 10.1158/1078-0432.Ccr-10-2405 |
0.701 |
|
| 2010 |
Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Reviews. Cancer. 10: 760-74. PMID 20966921 DOI: 10.1038/Nrc2947 |
0.727 |
|
| 2010 |
Price KA, Azzoli CG, Krug LM, Pietanza MC, Rizvi NA, Pao W, Kris MG, Riely GJ, Heelan RT, Arcila ME, Miller VA. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 1623-9. PMID 20871262 DOI: 10.1097/Jto.0B013E3181Ec1531 |
0.52 |
|
| 2010 |
Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, Han X, Tian W, Pao W, Chen H, Ji H. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4616-20. PMID 20855837 DOI: 10.1200/Jco.2010.29.6038 |
0.511 |
|
| 2010 |
Azzoli CG, Baker S, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, et al. [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer]. Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer. 13: 171-89. PMID 20681066 DOI: 10.3779/J.Issn.1009-3419.2010.03.15 |
0.332 |
|
| 2010 |
Chmielecki J, Peifer M, Jia P, Socci ND, Hutchinson K, Viale A, Zhao Z, Thomas RK, Pao W. Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. Nucleic Acids Research. 38: 6985-96. PMID 20587502 DOI: 10.1093/Nar/Gkq579 |
0.608 |
|
| 2010 |
Gao B, Sun Y, Zhang J, Ren Y, Fang R, Han X, Shen L, Liu XY, Pao W, Chen H, Ji H. Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 1130-5. PMID 20559149 DOI: 10.1097/Jto.0B013E3181E05016 |
0.501 |
|
| 2010 |
Zhao B, Oxnard GR, Moskowitz CS, Kris MG, Pao W, Guo P, Rusch VM, Ladanyi M, Rizvi NA, Schwartz LH. A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4647-53. PMID 20534736 DOI: 10.1158/1078-0432.Ccr-10-0125 |
0.302 |
|
| 2010 |
Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 1048-53. PMID 20512075 DOI: 10.1200/Jco.2010.28.15_Suppl.7572 |
0.496 |
|
| 2010 |
Redente EF, Dwyer-Nield LD, Merrick DT, Raina K, Agarwal R, Pao W, Rice PL, Shroyer KR, Malkinson AM. Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization. The American Journal of Pathology. 176: 2972-85. PMID 20431028 DOI: 10.2353/Ajpath.2010.090879 |
0.368 |
|
| 2010 |
Sun YH, Fang R, Gao B, Han XK, Zhang JH, Pao W, Chen HQ, Ji HB. Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers Acta Pharmacologica Sinica. 31: 647-648. PMID 20418893 DOI: 10.1038/Aps.2010.43 |
0.475 |
|
| 2010 |
Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. Journal of Neuro-Oncology. 99: 283-6. PMID 20146086 DOI: 10.1007/S11060-010-0128-6 |
0.519 |
|
| 2010 |
Girard N, Lou E, Azzoli CG, Reddy R, Robson M, Harlan M, Orlow I, Yatabe Y, Nafa K, Ladanyi M, Viale A, Kris MG, Riely G, Miller V, Klein RJ, ... ... Pao W, et al. Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 755-63. PMID 20068085 DOI: 10.1158/1078-0432.Ccr-09-2437 |
0.406 |
|
| 2010 |
Solomon SB, Zakowski MF, Pao W, Thornton RH, Ladanyi M, Kris MG, Rusch VW, Rizvi NA. Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. Ajr. American Journal of Roentgenology. 194: 266-9. PMID 20028932 DOI: 10.2214/Ajr.09.2858 |
0.488 |
|
| 2010 |
Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, Lynch T, Johnson BE, Miller VA. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 357-60. PMID 19949011 DOI: 10.1200/Jco.2009.24.7049 |
0.603 |
|
| 2010 |
Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nature Genetics. 42: 77-82. PMID 19946270 DOI: 10.1038/Ng.491 |
0.426 |
|
| 2010 |
Girard N, Deshpande C, Azzoli CG, Rusch VW, Travis WD, Ladanyi M, Pao W. Use of epidermal growth factor receptor/kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: Comparison with clinical guidelines Chest. 137: 46-52. PMID 19376842 DOI: 10.1378/Chest.09-0325 |
0.529 |
|
| 2010 |
Yeo W, Riely GJ, Yeap B, Lau MW, Warner J, Bodio KA, Kris MG, Pao W, Kobayashi S, Costa DB. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. Journal of Clinical Oncology. 28: 7572-7572. DOI: 10.1200/jco.2010.28.15_suppl.7572 |
0.432 |
|
| 2010 |
Oxnard GR, Riely GJ, Arcila MH, Kris MG, Pao W, Ladanyi M, Miller VA. Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI). Journal of Clinical Oncology. 28: 7520-7520. DOI: 10.1200/JCO.2010.28.15_SUPPL.7520 |
0.35 |
|
| 2010 |
D'Angelo SP, Janjigian YY, Kris MG, Pao W, Riely GJ, Marks J, Sima C, Dycoco J, Park BJ, Azzoli CG. Impact of EGFR and KRAS mutations on survival in 1,000 patients with resected lung adenocarcinoma. Journal of Clinical Oncology. 28: 7011-7011. DOI: 10.1200/JCO.2010.28.15_SUPPL.7011 |
0.418 |
|
| 2010 |
Gills JJ, Morrow B, Kawabata S, Mercado J, Hennessy B, Kunnumakkara AB, Pao W, Dennis PA. Abstract 624: Synergistic effects of combining the Akt inhibitor triciribine with erlotinib in EGFR TKI-resistant NSCLC Cancer Research. 70: 624-624. DOI: 10.1158/1538-7445.Am10-624 |
0.564 |
|
| 2010 |
Lovly CM, Stanchina Ed, Liang C, Pao W. Abstract 1788: Preclinical development of a selective, potent small molecule ALK inhibitor Cancer Research. 70: 1788-1788. DOI: 10.1158/1538-7445.Am10-1788 |
0.484 |
|
| 2010 |
Yeo W, Riely GJ, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB. Abstract 1784: Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations Cancer Research. 70: 1784-1784. DOI: 10.1158/1538-7445.Am10-1784 |
0.531 |
|
| 2010 |
Chmielecki J, Pietanza MC, Kris M, Miller V, Stout T, Pao W. Abstract 1774: Selection for the EGFR T790M gatekeeper resistance mutation may vary among different small molecule EGFR TKIs Cancer Research. 70: 1774-1774. DOI: 10.1158/1538-7445.Am10-1774 |
0.688 |
|
| 2010 |
Chmielecki J, Peifer M, Jia P, Socci ND, Hutchinson K, Viale A, Zhao Z, Thomas RK, Pao W. Abstract A18: A novel targeted capture and massively parallel sequencing platform for systematic discovery of tyrosine kinase fusions in cancer Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcme10-A18 |
0.6 |
|
| 2009 |
Arcila ME, Riely GJ, Zakowski MF, Kris MG, Ladanyi M, Pao W, Miller VA. Rebiopsy of patients (pts) with acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8025. PMID 27962836 DOI: 10.1200/Jco.2009.27.15_Suppl.8025 |
0.553 |
|
| 2009 |
Johnson ML, Rizvi NA, Ginsberg MS, Miller VA, Kris MG, Pao W, Riely GJ. A phase II trial of salirasib in patients with stage IIIB/IV lung adenocarcinoma enriched for KRAS mutations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8012. PMID 27962781 DOI: 10.1200/Jco.2009.27.15_Suppl.8012 |
0.479 |
|
| 2009 |
Gong Y, Yao E, Arcila M, Frankel S, Teruya-Feldstein J, Zakowski M, Thomas R, Ladanyi M, Pao W. Expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8095. PMID 27962673 DOI: 10.1200/Jco.2009.27.15_Suppl.8095 |
0.306 |
|
| 2009 |
Girard N, Klein R, Riely GJ, Reddy R, Kris MG, Pao W. Use of an Internet-based protocol to collect clinical information and blood from patients with lung cancer who never smoked cigarettes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e19064. PMID 27962136 DOI: 10.1200/Jco.2009.27.15_Suppl.E19064 |
0.408 |
|
| 2009 |
Azzoli CG, Baker S, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6251-66. PMID 19917871 DOI: 10.1200/Jco.2009.23.5622 |
0.443 |
|
| 2009 |
Gong Y, Yao E, Shen R, Goel A, Arcila M, Teruya-Feldstein J, Zakowski MF, Frankel S, Peifer M, Thomas RK, Ladanyi M, Pao W. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). Plos One. 4: e7273. PMID 19806209 DOI: 10.1371/Journal.Pone.0007273 |
0.304 |
|
| 2009 |
Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, Heynck S, Stückrath I, Weiss J, Fischer F, Michel K, Goel A, Regales L, Politi KA, Perera S, ... ... Pao W, et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proceedings of the National Academy of Sciences of the United States of America. 106: 18351-6. PMID 19805051 DOI: 10.1073/Pnas.0907325106 |
0.435 |
|
| 2009 |
Girard N, Deshpande C, Lau C, Finley D, Rusch V, Pao W, Travis WD. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. The American Journal of Surgical Pathology. 33: 1752-64. PMID 19773638 DOI: 10.1097/Pas.0B013E3181B8Cf03 |
0.443 |
|
| 2009 |
Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, Koutcher JA, Spassova M, Ouerfelli O, Mellinghoff IK, Zakowski MF, Politi KA, Pao W. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. The Journal of Clinical Investigation. 119: 3000-10. PMID 19759520 DOI: 10.1172/Jci38746 |
0.605 |
|
| 2009 |
Rudin CM, Avila-Tang E, Harris CC, Herman JG, Hirsch FR, Pao W, Schwartz AG, Vahakangas KH, Samet JM. Lung cancer in never smokers: molecular profiles and therapeutic implications. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5646-61. PMID 19755392 DOI: 10.1158/1078-0432.Ccr-09-0377 |
0.486 |
|
| 2009 |
Pao W, Kris MG, Iafrate AJ, Ladanyi M, Jänne PA, Wistuba II, Miake-Lye R, Herbst RS, Carbone DP, Johnson BE, Lynch TJ. Integration of molecular profiling into the lung cancer clinic. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5317-22. PMID 19706816 DOI: 10.1158/1078-0432.Ccr-09-0913 |
0.461 |
|
| 2009 |
Girard N, Ostrovnaya I, Lau C, Park B, Ladanyi M, Finley D, Deshpande C, Rusch V, Orlow I, Travis WD, Pao W, Begg CB. Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5184-90. PMID 19671847 DOI: 10.1158/1078-0432.Ccr-09-0594 |
0.478 |
|
| 2009 |
Horn L, Pao W. EML4-ALK: Honing in on a new target in non-small-cell lung cancer Journal of Clinical Oncology. 27: 4232-4236. PMID 19667260 DOI: 10.1200/Jco.2009.23.6661 |
0.463 |
|
| 2009 |
Chitale D, Gong Y, Taylor BS, Broderick S, Brennan C, Somwar R, Golas B, Wang L, Motoi N, Szoke J, Reinersman JM, Major J, Sander C, Seshan VE, Zakowski MF, ... ... Pao W, et al. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene. 28: 2773-83. PMID 19525976 DOI: 10.1038/Onc.2009.135 |
0.574 |
|
| 2009 |
Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proceedings of the National Academy of Sciences of the United States of America. 106: 9435-40. PMID 19478061 DOI: 10.1073/Pnas.0900571106 |
0.672 |
|
| 2009 |
Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, Michel K, Peifer M, Mermel C, Girard L, Peyton M, ... ... Pao W, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Research. 69: 3256-61. PMID 19351834 DOI: 10.1158/0008-5472.Can-08-4055 |
0.591 |
|
| 2009 |
Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer Proceedings of the American Thoracic Society. 6: 201-205. PMID 19349489 DOI: 10.1513/pats.200809-107LC |
0.539 |
|
| 2009 |
Zakowski MF, Hussain S, Pao W, Ladanyi M, Ginsberg MS, Heelan R, Miller VA, Rusch VW, Kris MG. Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. Archives of Pathology & Laboratory Medicine. 133: 470-7. PMID 19260752 DOI: 10.1043/1543-2165-133.3.470 |
0.526 |
|
| 2008 |
Riely GJ, Kris MG, Marks JL, Li A, Chitale DA, Riedel ER, Hsu M, Pao W, Miller VA, Ladanyi M. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 8006. PMID 27949005 DOI: 10.1200/jco.2008.26.15_suppl.8006 |
0.323 |
|
| 2008 |
Costa DB, Cho BC, Sequist LV, Riely GJ, Halmos B, Kim J, Huberman MS, Pao W, Tenen DG, Kobayashi S. Lack of efficacy of erlotinib in most EGFR mutated non-small cell lung cancers (NSCLCs) with acquired resistance to gefitinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 8105. PMID 27948816 DOI: 10.1200/jco.2008.26.15_suppl.8105 |
0.464 |
|
| 2008 |
Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A, Janakiraman M, Taylor BS, Pao W, Toyooka S, Ladanyi M, Gazdar A, et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Research. 68: 9375-83. PMID 19010912 DOI: 10.1158/0008-5472.Can-08-2223 |
0.608 |
|
| 2008 |
Bean J, Riely GJ, Balak M, Marks JL, Ladanyi M, Miller VA, Pao W. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7519-25. PMID 19010870 DOI: 10.1158/1078-0432.Ccr-08-0151 |
0.565 |
|
| 2008 |
Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Jänne PA, Huberman MS, Pao W, Tenen DG, Kobayashi S. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7060-7. PMID 18981003 DOI: 10.1158/1078-0432.Ccr-08-1455 |
0.585 |
|
| 2008 |
Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, ... ... Pao W, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 455: 1069-75. PMID 18948947 DOI: 10.1038/Nature07423 |
0.52 |
|
| 2008 |
Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, Nafa K, Riedel ER, Hsu M, Pao W, Miller VA, Ladanyi M. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5731-4. PMID 18794081 DOI: 10.1200/Jco.2008.26.15_Suppl.8006 |
0.478 |
|
| 2008 |
Marks JL, Gong Y, Chitale D, Golas B, McLellan MD, Kasai Y, Ding L, Mardis ER, Wilson RK, Solit D, Levine R, Michel K, Thomas RK, Rusch VW, Ladanyi M, ... Pao W, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Research. 68: 5524-8. PMID 18632602 DOI: 10.1158/0008-5472.Can-08-0099 |
0.585 |
|
| 2008 |
Marks JL, Golas B, Kirchoff T, Miller VA, Riely GJ, Offit K, Pao W. EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations Journal of Thoracic Oncology. 3: 805. PMID 18594331 DOI: 10.1097/Jto.0B013E31817E4664 |
0.533 |
|
| 2008 |
Yang CH, Yu CJ, Shih JY, Chang YC, Hu FC, Tsai MC, Chen KY, Lin ZZ, Huang CJ, Shun CT, Huang CL, Bean J, Cheng AL, Pao W, Yang PC. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2745-53. PMID 18509184 DOI: 10.1200/Jco.2007.15.6695 |
0.475 |
|
| 2008 |
Lyustikman Y, Momota H, Pao W, Holland EC. Constitutive activation of raf-1 induces glioma formation in mice Neoplasia. 10: 501-510. PMID 18472967 DOI: 10.1593/Neo.08206 |
0.313 |
|
| 2008 |
Ladanyi M, Pao W. Lung adenocarcinoma: Guiding EGFR-targeted therapy and beyond Modern Pathology. 21. PMID 18437168 DOI: 10.1038/Modpathol.3801018 |
0.561 |
|
| 2008 |
Li AR, Chitale D, Riely GJ, Pao W, Miller VA, Zakowski MF, Rusch V, Kris MG, Ladanyi M. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. The Journal of Molecular Diagnostics : Jmd. 10: 242-8. PMID 18403609 DOI: 10.2353/Jmoldx.2008.070178 |
0.547 |
|
| 2008 |
Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1472-8. PMID 18349398 DOI: 10.1200/Jco.2007.13.0062 |
0.472 |
|
| 2008 |
Marks JL, Broderick S, Zhou Q, Chitale D, Li AR, Zakowski MF, Kris MG, Rusch VW, Azzoli CG, Seshan VE, Ladanyi M, Pao W. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 3: 111-6. PMID 18303429 DOI: 10.1097/Jto.0B013E318160C607 |
0.571 |
|
| 2008 |
Azzoli CG, Park BJ, Pao W, Zakowski M, Kris MG. Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: A time for excitement and equipoise Journal of Thoracic Oncology. 3: 84-93. PMID 18166846 DOI: 10.1097/Jto.0B013E31815Efe24 |
0.418 |
|
| 2008 |
Bean J, Riely GJ, Balak M, Marks JL, Ladanyi M, Miller VA, Pao W. Acquired resistance to epidermal growth factor receptor (EGFR) kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma Journal of Clinical Oncology. 26: 8056-8056. DOI: 10.1200/JCO.2008.26.15_SUPPL.8056 |
0.484 |
|
| 2007 |
Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, ... ... Pao W, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proceedings of the National Academy of Sciences of the United States of America. 104: 20932-7. PMID 18093943 DOI: 10.1073/Pnas.0710370104 |
0.584 |
|
| 2007 |
Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, Bromberg JF. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. The Journal of Clinical Investigation. 117: 3846-56. PMID 18060032 DOI: 10.1172/Jci31871 |
0.449 |
|
| 2007 |
Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, ... ... Pao W, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 450: 893-8. PMID 17982442 DOI: 10.1038/Nature06358 |
0.446 |
|
| 2007 |
Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, Jiang X, Pao W. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. Plos Medicine. 4: e294. PMID 17927446 DOI: 10.1371/Journal.Pmed.0040294 |
0.723 |
|
| 2007 |
Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, Tyson L, Pao W, Rizvi NA, Schwartz LH, Miller VA. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus Clinical Cancer Research. 13: 5150-5155. PMID 17785570 DOI: 10.1158/1078-0432.Ccr-07-0560 |
0.497 |
|
| 2007 |
Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: Searching for the ideal method - Commentary on Hoshi et al., p. 4974 Clinical Cancer Research. 13: 4954-4955. PMID 17785543 DOI: 10.1158/1078-0432.Ccr-07-1387 |
0.513 |
|
| 2007 |
Regales L, Balak MN, Gong Y, Politi K, Sawai A, Le C, Koutcher JA, Solit DB, Rosen N, Zakowski MF, Pao W. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. Plos One. 2: e810. PMID 17726540 DOI: 10.1371/Journal.Pone.0000810 |
0.585 |
|
| 2007 |
Milton DT, Riely GJ, Azzoli CG, Gomez JE, Heelan RT, Kris MG, Krug LM, Pao W, Pizzo B, Rizvi NA, Miller VA. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer Cancer. 110: 599-605. PMID 17577220 DOI: 10.1002/Cncr.22816 |
0.402 |
|
| 2007 |
Marks JL, McLellan MD, Zakowski MF, Lash AE, Kasai Y, Broderick S, Sarkaria IS, Pham D, Singh B, Miner TL, Fewell GA, Fulton LL, Mardis ER, Wilson RK, Kris MG, ... ... Pao W, et al. Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. Plos One. 2: e426. PMID 17487277 DOI: 10.1371/Journal.Pone.0000426 |
0.533 |
|
| 2007 |
Pao W. Monitoring EGFR-mutant lung cancers by means of the blood. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 1: 199-200. PMID 17409855 DOI: 10.1016/s1556-0864(15)31566-5 |
0.393 |
|
| 2007 |
Broderick SR, Chitale D, Motoi N, Gong Y, Pao W, Venkatraman E, Rusch V, Brennan C, Gerald W, Ladanyi M. Integrated genomic analysis of lung adenocarcinomas identifies loss of the MAPK phosphatase gene DUSP4 in most EGFR mutant tumors Journal of Clinical Oncology. 25: 7686-7686. DOI: 10.1200/Jco.2007.25.18_Suppl.7686 |
0.531 |
|
| 2007 |
Marks JL, McLellan MD, Kasai Y, Fulton LA, Mardis ER, Wilson RK, Zakowski MF, Rusch VW, Varmus HE, Pao W. Mutational analysis of EGFR signaling pathway genes in lung adenocarcinomas Journal of Clinical Oncology. 25: 7584-7584. DOI: 10.1200/Jco.2007.25.18_Suppl.7584 |
0.459 |
|
| 2007 |
Kris MG, Riely GJ, Azzoli CG, Heelan RT, Krug LM, Pao W, Milton DT, Moore E, Rizvi NA, Miller VA. Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial Journal of Clinical Oncology. 25: 7575-7575. DOI: 10.1200/jco.2007.25.18_suppl.7575 |
0.421 |
|
| 2007 |
Miller VA, Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale D, Nafa K, Pao W, Ladanyi M. Smoking history and frequency of somatic KRAS mutations in adenocarcinoma of the lung Journal of Clinical Oncology. 25: 7573-7573. DOI: 10.1200/Jco.2007.25.18_Suppl.7573 |
0.465 |
|
| 2007 |
Pao W, Gong Y, Balak M. In response [2] Clinical Cancer Research. 13: 3431. DOI: 10.1158/1078-0432.Ccr-07-0513 |
0.531 |
|
| 2007 |
Marks JL, Broderick S, Seshan VE, Zakowski MF, Li A, Wilson R, Kris MG, Ladanyi M, Rusch VW, Pao W. PD5-3-7: EGFR and KRAS mutations are molecular predictors of survival in resected lung adenocarcinoma Journal of Thoracic Oncology. 2: S480-S481. DOI: 10.1097/01.Jto.0000283441.94583.Bc |
0.464 |
|
| 2007 |
Kris MG, Pao W, Zakowski MF, Ladanyi M, Heelan RT, Schwartz L, Zhao B, Venkatraman E, Rusch V, Rizvi NA. D2-01: Prospective trial of preoperative gefitinib to correlate response with EGFR exon 19 and 21 mutations and to select patients for adjuvant gefitinib Journal of Thoracic Oncology. 2: S393. DOI: 10.1097/01.Jto.0000283257.69605.2B |
0.451 |
|
| 2006 |
Christiani DC, Pao W, DeMartini JC, Linnoila RI, Malkinson AM, Onn A, Politi KA, Sharp M, Wong KK, Kim K. BAC consensus conference, November 4-6, 2004: epidemiology, pathogenesis, and preclinical models. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 1: S2-7. PMID 17409996 |
0.305 |
|
| 2006 |
Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 7232-41. PMID 17189394 DOI: 10.1158/1078-0432.Ccr-06-0658 |
0.56 |
|
| 2006 |
Pao W. Defining clinically relevant molecular subsets of lung cancer Cancer Chemotherapy and Pharmacology. 58. PMID 17093937 DOI: 10.1007/S00280-006-0310-X |
0.611 |
|
| 2006 |
Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6494-501. PMID 17085664 DOI: 10.1158/1078-0432.Ccr-06-1570 |
0.567 |
|
| 2006 |
Milton DT, Azzoli CG, Heelan RT, Venkatraman E, Gomez JE, Kris MG, Krug LM, Pao W, Rizvi NA, Dunne M, Miller VA. A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer. 107: 1034-41. PMID 16878326 DOI: 10.1002/Cncr.22088 |
0.474 |
|
| 2006 |
Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes & Development. 20: 1496-510. PMID 16705038 DOI: 10.1101/Gad.1417406 |
0.586 |
|
| 2006 |
Pham D, Kris MG, Riely GJ, Sarkaria IS, McDonough T, Chuai S, Venkatraman ES, Miller VA, Ladanyi M, Pao W, Wilson RK, Singh B, Rusch VW. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 1700-4. PMID 16505411 DOI: 10.1200/Jco.2005.04.3224 |
0.487 |
|
| 2006 |
Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 839-44. PMID 16467097 DOI: 10.1158/1078-0432.Ccr-05-1846 |
0.584 |
|
| 2006 |
Pao W, Balak MN, Riely GJ, Li AR, Zakowski MF, Ladanyi M, Miller VA. Molecular analysis of NSCLC patients with acquired resistance to gefitinib or erlotinib Journal of Clinical Oncology. 24: 7078-7078. DOI: 10.1200/Jco.2006.24.18_Suppl.7078 |
0.567 |
|
| 2006 |
Riely GJ, Kris MG, Schwartz LH, Akhurst T, Zhao B, Milton DT, Moore E, Tyson L, Pao W, Miller VA. Prospective FDG-PET and CT assessment of discontinuation of erlotinib (E) or gefitinib (G) in patients with EGFR TKI sensitive non-small cell lung cancer (NSCLC) who subsequently progress radiographically on E or G ("acquired resistance") followed by re-initiation of E or G and the subsequent addition of everolimus (RAD001) Journal of Clinical Oncology. 24: 7065-7065. DOI: 10.1200/Jco.2006.24.18_Suppl.7065 |
0.43 |
|
| 2006 |
Kris MG, Pao W, Zakowski MF, Ladanyi M, Heelan RT, Schwartz L, Zhao B, Venkatraman E, Rusch V, Rizvi NA. Prospective trial with preoperative gefitinib to correlate lung cancer response with EGFR exon 19 and 21 mutations and to select patients for adjuvant therapy Journal of Clinical Oncology. 24: 7021-7021. DOI: 10.1200/Jco.2006.24.18_Suppl.7021 |
0.525 |
|
| 2006 |
Pao W. Monitoring EGFR-mutant lung cancers by means of the blood Journal of Thoracic Oncology. 1: 199-200. DOI: 10.1016/S1556-0864(15)31566-5 |
0.492 |
|
| 2006 |
Christiani DC, Pao W, DeMartini JC, Linnoila RI, Malkinson AM, Onn A, Politi KA, Sharp M, Kim K. BAC Consensus Conference, November 4–6, 2004: Epidemiology, Pathogenesis, and Preclinical Models Journal of Thoracic Oncology. 1: S2-S7. DOI: 10.1016/S1556-0864(15)30002-2 |
0.395 |
|
| 2005 |
Pham D, Kris MG, McDonough T, Riely GJ, Venkatraman ES, Pao W, Wilson RK, Miller VA, Singh B, Rusch VW. Estimation of the likelihood of epidermal growth factor receptor (EGFR) mutations based on cigarette smoking history in patients with adenocarcinoma of the lung. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7069. PMID 27944521 DOI: 10.1200/jco.2005.23.16_suppl.7069 |
0.452 |
|
| 2005 |
Pao W, McLellan MD, Pham DK, Singh B, Rusch VW, Zakowski MF, Miller VA, Kris MG, Wilson RK, Varmus HE. Mutational profiling of the oncogenome in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7021. PMID 27944458 DOI: 10.1200/Jco.2005.23.16_Suppl.7021 |
0.405 |
|
| 2005 |
Varmus H, Pao W, Politi K, Podsypanina K, Du YCN. Oncogenes come of age Cold Spring Harbor Symposia On Quantitative Biology. 70: 1-9. PMID 16869733 DOI: 10.1101/Sqb.2005.70.039 |
0.453 |
|
| 2005 |
Riely GJ, Pao W. Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: Is timing important? Cancer Biology and Therapy. 4: 1096-1097. PMID 16294020 DOI: 10.4161/Cbt.4.10.2102 |
0.369 |
|
| 2005 |
Lassman AB, Rossi MR, Raizer JJ, Razier JR, Abrey LE, Lieberman FS, Grefe CN, Lamborn K, Pao W, Shih AH, Kuhn JG, Wilson R, Nowak NJ, Cowell JK, DeAngelis LM, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 7841-50. PMID 16278407 DOI: 10.1158/1078-0432.Ccr-05-0421 |
0.392 |
|
| 2005 |
Pao W, Ladanyi M, Miller VA. Erlotinib in lung cancer. The New England Journal of Medicine. 353: 1739-41; author repl. PMID 16240471 |
0.334 |
|
| 2005 |
Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinoma Journal of Molecular Diagnostics. 7: 396-403. PMID 16049312 DOI: 10.1016/S1525-1578(10)60569-7 |
0.537 |
|
| 2005 |
Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH, Edeen PT, Floyd M, Ford JM, Grotzfeld RM, Herrgard S, Insko DE, ... ... Pao W, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proceedings of the National Academy of Sciences of the United States of America. 102: 11011-6. PMID 16046538 DOI: 10.1073/Pnas.0504952102 |
0.495 |
|
| 2005 |
Ren GP, Wang TY, Pan QL, Pao W, Huai J. Epidermal growth factor receptor mutations detected in tumors from Chinese "never smokers" with lung adenocarcinoma Chinese Medical Journal. 118: 769-771. PMID 15899142 |
0.395 |
|
| 2005 |
Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions Journal of Clinical Oncology. 23: 2556-2568. PMID 15767641 DOI: 10.1200/Jco.2005.07.799 |
0.591 |
|
| 2005 |
Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain Plos Medicine. 2: 0225-0235. PMID 15737014 DOI: 10.1371/Journal.Pmed.0020073 |
0.564 |
|
| 2005 |
Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. Plos Medicine. 2: e17. PMID 15696205 DOI: 10.1371/Journal.Pmed.0020017 |
0.565 |
|
| 2005 |
Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, Ben-Porat L, Sachs DL, Heelan RT, Miller VA. Practical management of patients with non-small-cell lung cancer treated with gefitinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 165-74. PMID 15557594 DOI: 10.1200/Jco.2005.04.057 |
0.511 |
|
| 2005 |
Milton DT, Kris MG, Azzoli CG, Gomez JE, Heelan R, Krug LM, Pao W, Pizzo B, Rizvi NA, Miller VA. Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 23: 7104-7104. DOI: 10.1200/jco.2005.23.16_suppl.7104 |
0.335 |
|
| 2005 |
Rizvi NA, Pao W, Kris MG, Rusch V, Ladanyi M, Ginex PK, Zakowski MF, Tyson LB, Heelan RT, Varmus H. A prospective study to correlate EGFR mutations with gefitinib response Journal of Clinical Oncology. 23: 7091-7091. DOI: 10.1200/Jco.2005.23.16_Suppl.7091 |
0.416 |
|
| 2005 |
Riely GJ, Miller VA, Pao W, Zakowski M, Ladanyi M, Heelan RT, Kris MG. Clinical characteristics and natural history of patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations treated with erlotinib or gefitinib Journal of Clinical Oncology. 23: 7085-7085. DOI: 10.1200/jco.2005.23.16_suppl.7085 |
0.48 |
|
| 2005 |
Hussain S, Zakowski MF, Kris MG, Ladanyi M, Pao W, Riely G, Rizvi N, Gomez JE, Miller V. Correlation of EGFR and KRAS mutation status, response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and survival with histologic subtypes of adenocarcinoma of the lung Journal of Clinical Oncology. 23: 7080-7080. DOI: 10.1200/jco.2005.23.16_suppl.7080 |
0.452 |
|
| 2005 |
Miller VA, Zakowski M, Riely GJ, Pao W, Hussain S, Ladanyi M, Heelan RT, Kris MG. EGFR mutation, immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) as predictors of sensitivity to erlotinib and gefitinib in patients (pts) with NSCLC Journal of Clinical Oncology. 23: 7031-7031. DOI: 10.1200/jco.2005.23.16_suppl.7031 |
0.399 |
|
| 2005 |
Zakowski M, Ladanyi M, Kris M, Rusch V, Pao W. P-690 EGFR and KRAS mutational analysis of mucinous pneumonicbronchiololavelolar carcinomas Lung Cancer. 49: S300. DOI: 10.1016/S0169-5002(05)81183-3 |
0.445 |
|
| 2005 |
Rizvi N, Pao W, Miller V, Rusch V, Heelan R, Ladanyi M, Ginex P, Tyson L, Zakowski M, Kris M. O-123 A prospective study to correlate EGFR mutations with gefitinib response in early stage NSCLC Lung Cancer. 49: S43. DOI: 10.1016/S0169-5002(05)80257-0 |
0.438 |
|
| 2005 |
Pham D, Sarkaria I, Socci N, Pao W, Zakowski M, Miller V, Kris M, Rusch V, Singh B. O-017 Lung adenocarcinomas with mutations in EGFR and KRAS havedistinct gene expression profiles Lung Cancer. 49: S9-S10. DOI: 10.1016/S0169-5002(05)80149-7 |
0.487 |
|
| 2004 |
Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proceedings of the National Academy of Sciences of the United States of America. 101: 13306-11. PMID 15329413 DOI: 10.1073/Pnas.0405220101 |
0.586 |
|
| 2004 |
Pao W, Miller VA, Venkamatraman E, Kris MG. Predicting sensitivity of non-small-cell lung cancer to gefitinib: Is there a role for P-Akt Journal of the National Cancer Institute. 96: 1117-1119. PMID 15292378 DOI: 10.1093/Jnci/Djh244 |
0.551 |
|
| 2004 |
Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, Tyson L, Venkatraman E, Ben-Porat L, Memoli N, Zakowski M, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1103-9. PMID 15020612 DOI: 10.1200/Jco.2004.08.158 |
0.518 |
|
| 2004 |
Pao W, Miller VA, Kris MG. 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa®) in non-small cell lung cancer (NSCLC) Seminars in Cancer Biology. 14: 33-40. PMID 14757534 DOI: 10.1016/J.Semcancer.2003.11.005 |
0.567 |
|
| 2004 |
Zhang F, Pao W, Umphress S, Jakowlew S, Meyer A, Dwyer-Nield L, Takeda K, Gelfand E, Fisher J, Malkinson A, Mason RJ. Serum Levels of Surfactant Protein D Are Increased in Mice With Lung Tumors Chest. 125: 109S. DOI: 10.1378/Chest.125.5_Suppl.109S-A |
0.316 |
|
| 2004 |
Pao W, Zakowski M, Cordon-Cardo C, Ben-Porat L, Kris MG, Miller VA. Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib Journal of Clinical Oncology. 22: 7025-7025. DOI: 10.1200/jco.2004.22.14_suppl.7025 |
0.392 |
|
| 2003 |
Pao W, Klimstra DS, Fisher GH, Varmus HE. Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance. Proceedings of the National Academy of Sciences of the United States of America. 100: 8764-9. PMID 12857957 DOI: 10.1073/Pnas.1133333100 |
0.305 |
|
| 2003 |
Zhang F, Pao W, Umphress S, Jackowlew S, Meyer AM, Dwyer-Nield L, Malkinson AM, Mason RJ. P-640 Serum levels of surfactant protein D are increased in mice with lung tumors Lung Cancer. 41. DOI: 10.1016/S0169-5002(03)92607-9 |
0.321 |
|
| 1998 |
Wen L, Barber DF, Pao W, Wong FS, Owen MJ, Hayday A. Primary γδ cell clones can be defined phenotypically and functionally as Th1/Th2 cells and illustrate the association of CD4 with Th2 differentiation Journal of Immunology. 160: 1965-1974. PMID 9469460 |
0.418 |
|
| 1997 |
Passoni L, Hoffman ES, Kim S, Crompton T, Pao W, Dong MQ, Owen MJ, Hayday AC. Intrathymic delta selection events in gammadelta cell development. Immunity. 7: 83-95. PMID 9252122 DOI: 10.1016/S1074-7613(00)80512-9 |
0.495 |
|
| 1996 |
Pao W, Wen L, Smith AL, Gulbranson-Judge A, Zheng B, Kelsoe G, MacLennan ICM, Owen MJ, Hayday AC. γδ T cell help of B cells is induced by repeated parasitic infection, in the absence of other T cells Current Biology. 6: 1317-1325. PMID 8939571 DOI: 10.1016/S0960-9822(02)70718-5 |
0.492 |
|
| 1996 |
Mallick-Wood CA, Pao W, Cheng AM, Lewis JM, Kulkarni S, Bolen JB, Rowley B, Tigelaar RE, Pawson T, Hayday AC. Disruption of epithelial gamma delta T cell repertoires by mutation of the Syk tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America. 93: 9704-9. PMID 8790395 DOI: 10.1073/Pnas.93.18.9704 |
0.544 |
|
| 1996 |
Dianda L, Gulbranson-Judge A, Pao W, Hayday AC, MacLennan LCM, Owen MJ. Germinal center formation in mice lacking αβ T cells European Journal of Immunology. 26: 1603-1607. PMID 8766567 DOI: 10.1002/Eji.1830260729 |
0.491 |
|
| 1996 |
Wen L, Pao W, Wong FS, Peng Q, Craft J, Zheng B, Kelsoe G, Dianda L, Owen MJ, Hayday AC. Germinal center formation, immunoglobulin class switching, and autoantibody production driven by "non α/β" T cells Journal of Experimental Medicine. 183: 2271-2282. PMID 8642336 DOI: 10.1084/Jem.183.5.2271 |
0.478 |
|
| 1996 |
Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T. Erratum: Syk tyrosine kinase required for mouse viability and B-cell development Nature. 379: 657-657. DOI: 10.1038/379657A0 |
0.524 |
|
| 1995 |
Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T. Syk tyrosine kinase required for mouse viability and B-cell development. Nature. 378: 303-6. PMID 7477353 DOI: 10.1038/378303A0 |
0.558 |
|
| 1991 |
Kyes S, Pao W, Hayday A. Influence of site of expression on the fetal γδ T-cell receptor repertoire Proceedings of the National Academy of Sciences of the United States of America. 88: 7830-7833. PMID 1652766 DOI: 10.1073/Pnas.88.17.7830 |
0.497 |
|
| Show low-probability matches. |
